Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Although substantial evidence suggests that treatment of dyslipidemia with statins reduces mortality and morbidity that are associated with cardiovascular disease , only a few studies have examined the efficacy of statins on inflammatory and fibrinolytic status in patients with chronic kidney disease ( CKD ) . A 6-mo , prospect i ve , r and omized study was design ed to assess the efficacy of atorvastatin in reducing circulating inflammatory and fibrinolytic parameters in patients with CKD . Sixty-six patients with CKD ( stages 2 , 3 , and 4 ) and LDL cholesterol levels > or = 100 mg/dl were r and omly assigned ( 2:1 ) to receive 20 mg/d atorvastatin ( n = 44 ) or nonatorvastatin therapy ( n = 22 ) . Lipid profile , renal function , fibrinolytic balance ( tissue plasminogen activator [ t-PA ] and plasminogen activator inhibitor-1 ) , and inflammatory markers ( C-reactive protein [ CRP ] , IL-1 beta , IL-6 , and TNF-alpha ) were measured before and 6 mo after atorvastatin was added to the treatment . Twenty-five age-matched individuals with normal renal function ( estimated GFR > 90 ml/min ) were used as healthy control subjects . Patients with CKD had higher CRP , IL-1 beta , TNF-alpha , and IL-6 levels than age-matched population with normal renal function . t-PA concentration was higher in patients with CKD ( P = 0.000 ) . Plasminogen activator inhibitor-1 values were comparable in all patients . Total cholesterol and LDL cholesterol were significantly reduced only in patients who received atorvastatin . In addition to the hypolipidemic effect , atorvastatin treatment significantly reduced inflammatory parameters : CRP ( median 4.1 to 2.9 ; P = 0.015 ) , TNF-alpha ( 6.0 + /- 2.7 to 4.7 + /- 2.4 ; P = 0.046 ) , and IL-1 beta levels ( 1.9 + /- 0.7 to 1.2 + /- 0.7 ; P = 0.001 ) . These parameters remained unchanged in patients who were not treated with atorvastatin . Fibrinolytic parameters were not modified by atorvastatin treatment . Patients with CKD showed higher levels of inflammatory parameters and t-PA levels than age-matched healthy control subjects . Atorvastatin treatment , in addition to its beneficial effect on cholesterol levels , improved the inflammatory state of these patients without modifying fibrinolytic balance
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .